Trial Radar KI | ||
|---|---|---|
Die klinische Studie NCT07413601 für Triple Negative Breast Cancer Metastatic ist noch nicht rekrutierend. In der Kartenansicht des Klinische Studien Radar und den KI-Entdeckungstools finden Sie alle Details. Oder stellen Sie hier Ihre Fragen. | ||
Eine Studie entspricht den Filterkriterien
Kartenansicht
Phase 2 Clinical Study of Iparomlimab and Tuvonralimab (QL1706) in Combination With Platinum Chemotherapy Versus Platinum Chemotherapy in the Treatment of Second-/Third-line Triple Negative Breast Cancer (TNBC) Phase 2 78 Randomisiert Offene Studie
Die Details der klinischen Studie sind hauptsächlich auf Englisch verfügbar. Trial Radar KI kann jedoch helfen! Klicken Sie einfach auf 'Studie erklären', um die Informationen zur Studie in der ausgewählten Sprache anzuzeigen und zu besprechen.
Die klinische Studie NCT07413601 untersucht Behandlung im Zusammenhang mit Triple Negative Breast Cancer Metastatic. Diese interventionsstudie der Phase 2 hat den Status noch nicht rekrutierend. Der Start ist für 10. Februar 2026 geplant, bis 78 Teilnehmer aufgenommen werden. Durchgeführt von Cancer Institute and Hospital, Chinese Academy of Medical Sciences wird der Abschluss für 10. Februar 2029 erwartet. Die Daten von ClinicalTrials.gov wurden zuletzt am 17. Februar 2026 aktualisiert.
Kurzbeschreibung
This study is an open-label, prospective, phase 2, randomized controlled study to evaluate the efficacy and safety of apolitovorrelizumab (QL1706) in combination with platinum chemotherapy versus platinum chemotherapy in the treatment of advanced unresectable and or metastatic triple negative breast cancer previously treated with first-line or second-line systems. It is planned to enroll 78 subjects in this study. Su...Mehr anzeigen
Offizieller Titel
Phase 2 Randomized Controlled Clinical Study of Iparomlimab and Tuvonralimab (QL1706) in Combination With Platinum Chemotherapy Versus Platinum Chemotherapy in the Treatment of Second-/Third-line Triple Negative Breast Cancer (TNBC)
Erkrankungen
Triple Negative Breast Cancer MetastaticWeitere Studien-IDs
- NCC5927
NCT-Nummer
Studienbeginn (tatsächlich)
2026-02-10
Zuletzt aktualisiert
2026-02-17
Studienende (vorauss.)
2029-02-10
Geplante Rekrutierung
78
Studientyp
Interventionsstudie
PHASE
Phase 2
Status
Noch nicht rekrutierend
Primäres Ziel
Behandlung
Zuteilungsmethode
Randomisiert
Interventionsmodell
Parallel
Verblindung
Keine (offene Studie)
Studienarme/Interventionen
| Teilnehmergruppe/Studienarm | Intervention/Behandlung |
|---|---|
ExperimentellExperimental | QL1706 IV infusion, 5mg/kg, given every 3 weeks, every 3 weeks as a cycle； Cisplatin/ Carboplatin Cisplatin: 75mg/m2, intravenous infusion, Day 1 (or divided into 3 days), every 3 weeks as cycles; carboplatin: AUC5, intravenous infusion, Day 1, every 3 weeks as cycles; |
ExperimentellControl Group | Cisplatin/ Carboplatin Cisplatin: 75mg/m2, intravenous infusion, Day 1 (or divided into 3 days), every 3 weeks as cycles; carboplatin: AUC5, intravenous infusion, Day 1, every 3 weeks as cycles; |
Hauptergebnismessungen
Nebenergebnismessungen
| Ergebnismessung | Beschreibung der Messung | Zeitrahmen |
|---|---|---|
Median Progression-Free Survival (PFS) | The time interval between the start of study drug use and the patient's disease progression or death. | From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 36 months |
| Ergebnismessung | Beschreibung der Messung | Zeitrahmen |
|---|---|---|
objective response rate（ORR） | Proportion of patients with complete response (CR) and partial response (PR) assessed according to RECIST 1.1 in solid tumors | assessed up to 36 months |
disease control rate（DCR） | Proportion of patients with complete response, partial response, and stable response as assessed according to RECIST 1.1 in solid tumors. | assessed up to 36 months |
duration of response | Time from the start of complete response (CR) or partial response (PR) on the first tumor assessment to progression of disease (PD) or death from any cause on the first tumor assessment | assessed up to 36 months |
overall survival（OS） | Time from start of study drug to death from any cause | assessed up to 36 months |
adverse events | Incidence of adverse events (AEs), serious adverse events (SAEs), treatment-related adverse events (TRAEs), immune-related adverse events (irAEs) | assessed up to 36 months |
Teilnahme-Assistent
Eignungskriterien
Zugelassene Altersgruppen
Erwachsene, Ältere Erwachsene
Mindestalter
18 Years
Zugelassene Geschlechter
Alle
- Age ≥18 years, regardless of gender;
- ECOG performance status: 0-1;
- Locally advanced or metastatic triple negative breast cancer confirmed by histopathology that is not suitable for curative treatment and cannot be treated surgically (Defined as negative for HER2, ER and PR expression according to the latest ASCO/CAP guidelines);
- Patients who have previously received first-line or second-line systemic treatment for locally advanced or metastatic breast cancer and have experienced recurrence within 12 months after the end of previous adjuvant therapy are counted as first-line systemic therapy;
- There is radiographic or objective evidence of disease progression at the last systemic treatment before or after the start of study treatment;
- Patients have at least one evaluable lesion (based on CT or MRI according to the RECIST 1.1 criteria);
- Tissue or blood samples for biomarker testing can be provided, tissue samples during the baseline period (try to provide tumor puncture tissue after recent progression, if not, previously archived tissue is also available, 5-10 white slides); blood samples during the baseline period, after 2 cycles of treatment and after progression;
- Good organ function：The bone marrow function must be tested within 14 days before enrollment, white blood cell count (WBC) ≥3.5×109/L, hemoglobin (Hb) ≥90g/L, absolute neutrophil count (ANC) ≥1.5×109/L, and platelets (PLT) ≥80×109/L, and have not received blood transfusion or biological response modifiers (such as granulocytes, erythrocyte growth factor, Shengxuebao, etc.) within 14 days before the first dose. Liver function: Liver function must be tested within 14 years before enrollment. Patients without liver metastasis require serum total bilirubin (TBIL) ≤1.5× upper limit of normal (ULN); alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤2.5×ULN. Requirements for patients with liver metastases: serum total bilirubin (TBIL) ≤1.5× the upper limit of normal (ULN); alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤5×ULN; alkaline phosphatase (ALP) ≤5×ULN in patients with liver metastases and no bone metastases, and ALP≤2.5×ULN in patients without liver and bone metastases. Renal function: Renal function should be tested within 14 days before enrollment, with blood creatinine ≤1.5×ULN or creatinine clearance ≥60mL/min (based on the Cockcroft-Gault formula). No serious cardiac dysfunction, left ventricular ejection fraction (LVEF) ≥50%(confirmed by ECHO) .Coagulation function: International normalized ratio (INR) ≤1.5×ULN and activated partial thromboplastin time (APTT) ≤1.5×ULN (unless receiving the*utic anticoagulant drugs).
- Patients of childbearing potential must use effective contraceptive measures during the study until 6 months after the last dose.
- The patient voluntarily joined the study and signed the informed consent form, with good compliance.
- Previous use of CTLA-4 monoclonal antibody or PD-1/PD-L1 and CTLA-4 bispecific antibodies (such as cardonilumab, KN046, etc.) or bifunctional combination antibodies (e.g., apolitto vorrelizumab);
- relapse within 6 months after the end of previous (new) adjuvant immune checkpoint inhibitor therapy; or progression-free survival of locally advanced or metastatic breast cancer receiving immune checkpoint inhibitor therapy; 6 months;
- relapse within 6 months after the end of previous (new) adjuvant platinum therapy; Or locally advanced or metastatic breast cancer receiving platinum therapy has a progression-free survival of <3 months (if the drug is discontinued due to non-tumor progression factors, but the duration of discontinuation is ≥3 months before randomization, you can participate in this study);
- Those who have experienced immune-related toxicity that led to permanent drug discontinuation during previous anti-tumor immunotherapy, or have experienced immune-related adverse events (irAEs) of ≥ grade 3 or immune-related myocarditis of ≥ grade 2 and are assessed by the investigator as not suitable for treatment in this study. Grade 3 endocrine abnormalities with stable control of hormone replacement therapy can be enrolled after the investigator assessed that these irAEs will not affect the administration of study drugs and safety assessment;
- Previous history of or concurrent interstitial pneumonia, severe chronic obstructive pulmonary disease, severe pulmonary dysfunction, symptomatic bronchospasm, etc.;
- Previous history of other primary malignant tumors; Note: Except for basal cell carcinoma of the skin, superficial bladder cancer, squamous cell carcinoma of the skin, or cervical cancer in situ; Or patients who have received radical treatment and have not relapsed within 5 years of treatment can participate in this trial;
- Have experienced severe allergic reactions to the pharmaceutical or inactive ingredients of the study drug;
- Adverse reactions from previous anti-tumor therapy have not recovered to NCI-CTCAE 5.0 grade evaluation ≤1 (Except for toxicities that are judged by the investigator to have no safety risks, such as hair loss);
- Have active autoimmune disease or have a history of autoimmune disease, are using immunosuppressants, or systemic hormone therapy (prednisone or other equivalent hormone at a dose>10mg/day), and continue to use it within 2 weeks prior to enrollment. Except for the following diseases: Clinically stable autoimmune thyroid disease; Type 1 diabetes treated with hormone replacement therapy; through local treatment (e.g., low-dose topical hormones) are well controlled and no autoimmune skin diseases requiring additional treatment due to acute exacerbation within 12 months prior to screening (such as eczema, psoriasis, chronic lichen simplex, or vitiligo with simple skin lesions accumulating less than 10% of the body surface area);
- Any serious or uncontrollable systemic disease, including hypertension that is not well controlled with drugs, according to the investigator's judgment (systolic blood pressure>160mmHg or diastolic blood pressure>100mmHg), uncontrolled diabetes, and signs of active bleeding, etc.;
- Uncontrolled cardiac disease, including heart failure of NYHA class 2 or above, unstable angina pectoris, myocardial infarction within 1 year, clinically significant supraventricular or ventricular arrhythmia requiring treatment, prolonged QT syndrome, such as QTc>450ms (men) or QTc>470ms (women);
- Evidence of active infection includes but is not limited to hepatitis B (both HBsAg positive and HBVDNA≥2000IU/mL, and hepatitis caused by drugs or other reasons is excluded), hepatitis C (both anti-HCV antibody positive and HCV RNA positive) or human immunodeficiency virus (HIV) infection;
- Women with positive serum pregnancy tests or nursing do not agree to use adequate contraceptive measures during the study and for 6 months after receiving the trial drug;
- Subjects with known central nervous system metastases and/or cancerous meningitis (except for: asymptomatic, or treatment-treated and stable, no new brain metastases or radiographic evidence of expansion of brain metastases has been found for at least 4 weeks after treatment for brain metastases, and steroid or anticonvulsant treatment has been discontinued for at least 14 days before the start of study treatment);
- Other circumstances that the investigator deems unsuitable for participation in this clinical trial.
Cancer Institute and Hospital, Chinese Academy of Medical SciencesVerantwortliche Partei
Ma Fei，MD, Hauptprüfer, Chief Physician, Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Zentrale Studienkontakte
Kontakt: MFei, +86 13710217780, [email protected]
1 Studienstandorte in 1 Ländern
Beijing Municipality
No. 17 Panjiayuan Nan Li, Chaoyang District, Beijing, Beijing, Beijing Municipality, 100021, China